Chagos deal cost is ‘going rate for best defensive real estate', says ex-FO boss
Britain is paying the 'going rate as a tenant for… the best defensive real estate in the whole Indian Ocean', a former Foreign Office chief has said as he backed the Chagos Islands deal that is set to cost the taxpayer billions of pounds.
Hitting out at critics who argued the UK should ignore a legal ruling to hand over the archipelago to Mauritius, Lord McDonald of Salford argued this was what 'the powerful and unprincipled do', such as Russia.
The independent crossbencher, a former ambassador who headed the Foreign Office from 2015 to 2020, spoke in support of the agreement in the face of strong objections at Westminster, with opponents branding it a 'surrender' and 'gross folly' funded by the public.
The deal signed last month after long-running negotiations, started under the previous Tory administration, returns sovereignty of the Chagos Islands to Mauritius, but will see Britain lease back the strategically important military base on Diego Garcia.
It follows a 2019 advisory opinion by the International Court of Justice, which said the UK should cede control.
As well as establishing a £40 million fund for Chagossians expelled from the islands, the UK has agreed to pay Mauritius at least £120 million annually during the duration of the 99-year agreement, a total cost in cash terms of at least £13 billion.
The Government, however, estimates the bill will be lower at around £101 million a year, while critics argue it will be much higher.
The deal could also be extended in the future for an extra 40 years, provided agreement is reached.
In a recent report, the House of Lords International Agreements Committee (HLIAC) said although 'not perfect', the treaty must be ratified to avoid legal challenges that could threaten UK control of the military base.
Its members warned Mauritius was 'likely' to resume its campaign to secure a binding judgment on sovereignty against Britain unless the agreement was approved and concluded the Government 'cannot ignore' the risk of an 'adverse ruling' putting Britain's right to run the joint UK-US site in jeopardy.
Speaking at Westminster as peers debated the controversial accord, Lord McDonald said: 'The most damaging blow to any country's international reputation is a justified charge of hypocrisy.
'The United Kingdom stands for the rule of law in all circumstances. We lose credibility when we seek exceptions to this principle for ourselves.'
He added: 'Opponents dislike the expense of the deal.
'Well, we're paying the going rate as a tenant for a base in the wider Indian Ocean, somewhat more than the French in Djibouti, but we're getting more for more.
'Diego Garcia is the best defensive real estate in the whole Indian Ocean.
'Even though £101 million per year is a lot, it's a lot less than the Americans pay to run the base.
'It's a joint base, and we're paying our way in the joint effort.'
Lord McDonald also disputed the agreement would bolster China's presence in the Indian Ocean, arguing that 'our partner in Delhi looms much larger in Mauritian calculations than our challenger in Beijing'.
He went on: 'Confronted by a charge of double standards, some opponents of this agreement shrug their shoulders. They think they can get away with it, tough it out. But that is what the powerful and unprincipled do. That is what Russia does.'
The peer added: 'It gives the UK and our American allies a secure presence in the archipelago for the next 140 years.
'It enhances our security and restores our reputation as a country respecting international law, even when inconvenient and costly.'
But Tory shadow foreign minister Lord Callanan said: 'This agreement amounts to a retreat, a surrender of sovereign territory that serves as a linchpin of our defence architecture at a time when authoritarian threats are rising and alliances matter more than ever.
'Handing control to a government who align themselves ever more closely with Beijing – a regime that actively undermines international norms and our national interests – is not only unwise, it is positively dangerous.
'To compound the error, the British taxpayer is being made to foot the bill.'
He added: 'This whole affair has been a gross folly. There is no strategic gain here, no credible guarantee for the future of Diego Garcia and no reassurance for our allies.
'Instead, we send a message to adversaries and allies alike that British sovereignty is indeed negotiable. It is capitulation and we must reject it.'
Pointing out the Tories in office had opened negotiations to cede sovereignty, Liberal Democrat Lord Purvis of Tweed said: 'The treaty is a consequence of now completing the previous Conservative government's policy.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Are Options Traders Betting on a Big Move in Bristol-Myers Squibb Stock?
Investors in Bristol-Myers Squibb Company BMY need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $25 Call had some of the highest implied volatility of all equity options today. Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. Clearly, options traders are pricing in a big move for Bristol-Myers Squibb shares, but what is the fundamental picture for the company? Currently, Bristol-Myers Squibb is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Top 36% of our Zacks Industry Rank. Over the last 60 days, one analyst increased the earnings estimates for the current quarter, while three have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.66 per share to $1.53 in that period. Given the way analysts feel about Bristol-Myers Squibb right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk. Click to see the trades now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
40 minutes ago
- Yahoo
1 sneaky UK growth stock to consider in July
Growth stocks come in all shares and sizes. You've obviously got the likes of Nvidia (NVDA), with its eye-popping growth rates, or Rolls-Royce (RR.L), which has positively transformed its profit margins. Then there's WH Smith (SMWH.L), which is a UK stock that may raise a few eyebrows when associated with growth. After all, many people might still associate the company with its high street stores, the first of which opened in London in 1792. But, sadly, there isn't much growth happening today on British high streets. E-commerce and high taxes are doing the irreversible damage there. In March, WH Smith announced it would sell its 480 high street shops to Modella Capital for £52m in gross cash proceeds. However, it announced today (30 June) that it now expects up to £40m. This will be made up of £10m expected in FY25, up to £20m in FY26, and £10m of deferred tax assets to be realised later. In other words, it's accepting £12m less to get the deal done, after a recent period of softer trading forced Modella to renegotiate the original deal. In response, the WH Smith share price dropped as much as 5% today, before clawing back some losses. It's now trading 2.5% lower at 1,100p. Here's why I think this FTSE 250 (^FTMC) stock is worth considering at this price. This transaction now positions WH Smith, which is keeping its brand, as a travel retailer. As the company puts it, 'This creates a pure play global travel retailer which is well positioned to capture the substantial global growth opportunities in its key markets and drive enhanced shareholder value'. Unlike the falling footfall and unappealing economics of the high street, global travel is a structural growth market. Over the next couple of decades, global airport passenger numbers are expected to double, and that will need a lot of investment in airport infrastructure. WH Smith already operates around 1,300 stores in airports, train stations, and hospitals across 32 countries worldwide. While growth at UK travel hubs is likely to remain limited due to opposition on environmental grounds, the Asia-Pacific and Middle East regions are expected to lead the charge. I like this pivot, as the challenges WH Smith faced on the high street aren't nearly as strong in travel retail. At airports and train stations, there's a captive audience with time to kill and far fewer alternatives. No one's browsing Amazon (AMZN) for a bottle of water or the neck pillow they forgot to pack! Back in FY19, WH Smith reported revenue of £1.4bn and a £106m net profit. Then the pandemic hit the business like a sledgehammer, resulting in losses and higher debt. For FY26, which starts in September, revenue is expected to be £1.74bn, with a net profit of £114m. Yet the share price is still more than 50% lower than before Covid, despite the firm bouncing back strongly. Indeed, it's gone nowhere for five years now! Looking ahead, the company expects headline net debt to increase to £425m by August, above previous expectations for £400m. So the balance sheet is a risk worth watching. However, the stock looks cheap enough to consider, in my opinion. It's trading for less than 13 times forward earnings, while offering a 3% dividend yield. The post 1 sneaky UK growth stock to consider in July appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Ben McPoland has positions in Nvidia and Rolls-Royce Plc. The Motley Fool UK has recommended Amazon, Nvidia, Rolls-Royce Plc, and WH Smith. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Associated Press
an hour ago
- Associated Press
Iksuda Therapeutics Receives FDA IND Clearance for IKS014
NEWCASTLE, England--(BUSINESS WIRE)--Jun 30, 2025-- Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IKS014, a human epidermal growth factor receptor 2 (HER2) ADC targeting patients with advanced HER2+ solid tumours, enabling the expansion of ongoing clinical trials. IKS014 is currently being investigated in an open-label phase 1 dose-escalation study ( ) designed to evaluate the safety and tolerability of increasing dose levels of IKS014 and establish a recommended phase 2 dose. Preliminary data from this study has demonstrated promising clinical activity across multiple tumour types, including breast, ovarian, gallbladder, and oesophageal cancers, and including patients who have relapsed after prior treatment with Enhertu. Gaining access to U.S. centres for the dose expansion stage of this phase 1 trial will enable efficient confirmation of the role of IKS014 in this important patient sub-set. Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, said: 'The FDA clearance of our IND application for IKS014 represents a significant milestone in our mission to address the critical unmet needs of patients with HER2-positive cancers, particularly those who have exhausted current standard-of-care options. Early clinical data has been extremely encouraging, and we are excited to expand our program to reach more patients. 'The early efficacy signals that have been observed, particularly in patients that have relapsed after receiving prior treatments of Kadcyla and Enhertu, suggest IKS014 could potentially offer a new treatment option for patients who currently have limited alternatives. We look forward to working with our clinical partners to further evaluate the potential of IKS014.' The first stage of this phase 1 trial, to determine the recommended phase 2 dose for dose expansion, is nearing completion. The expansion phase will assess several patient cohorts including those with HER2-positive breast cancer who are refractory to or cannot tolerate Enhertu, patients with HER2-low breast cancer and patients with HER2-positive positive gastric cancer. The IND clearance will allow Iksuda to access patients across sites in the United States, alongside sites in Australia, New Zealand, and Singapore. The phase 1 trial is expected to complete in 2H 2026. About IKS014 IKS014 is a potential best-in-class antibody drug conjugate, benefiting from tumour selective activation and release of the cytotoxic agent monomethyl auristatin F (MMAF). In preclinical trials, it displayed impressive activity in high- and low-HER2 expressing tumours with a favourable Therapeutic Index vs other HER2-directed drugs. Iksuda gained exclusive world-wide rights (excluding Greater China and South Korea) to IKS014 from LigaChem Biosciences ( ). About Iksuda Therapeutics: Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda's pipeline of ADCs is centred on a portfolio of prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink ® platform. The Company's design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer. View source version on CONTACT: For further information please contact: Iksuda Therapeutics Dave Simpson, Chief Executive Officer Tel: +44 (0) 191 6031680 [email protected] Consulting (Financial Media and IR) Simon Conway / Rob Winder / Amy Byrne Tel: +44 (0) 020 3727 1000 [email protected] KEYWORD: NORTH AMERICA UNITED STATES IRELAND UNITED KINGDOM EUROPE MASSACHUSETTS INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH FDA CLINICAL TRIALS SOURCE: Iksuda Therapeutics Copyright Business Wire 2025. PUB: 06/30/2025 08:00 PM/DISC: 06/30/2025 08:00 PM